DVA Davita Inc. stock chart & analysis
Conviction 45HealthcareScan · Fri, Nov 6, 2026Davita Inc. (DVA) closed at $191.35 (-1.78%) on Nov 6, 2026. Price is above its 50-day and above its 200-day moving average. RSI(14) 56, RS Rating 93, -22.7% from its 52-week high, +68.4% year to date. Sector: Healthcare · Services-Misc Health & Allied Services, Nec.
Financials as of Wed, Sep 30, 2026 · quarterly.
DVA technical analysis
Trend
DVA is in an uptrend: price is above the 50-day, which is above the 200-day moving average. It closed 4.8% above the 50-day ($182.59) and 6.9% above the 200-day ($179.10). ADX(14) at 12 points to a weak trend — more range than direction. It meets 7 of 8 trend-template criteria.
Momentum
RSI(14) is 56, in the bullish half of its range. The MACD histogram is positive. A bearish MACD divergence is in place. Its RS Rating of 93 puts its weighted 12-month performance ahead of about 93% of the US market.
Volume and volatility
Volume on the latest session ran 0.8× its 20-day average. It trades about $158.8M a day on average. ATR(14) is $7.15, 3.7% of price — its typical daily range. Chaikin Money Flow (0.27) shows accumulation.
Key levels
The chart pattern's support is $171.12 and its resistance $196.36. The 52-week range is $101.00 to $247.49; price is 22.7% below the high and 89.5% above the low. The VWAP anchored at the 52-week high is $186.30, below price.
Performance
DVA returned +2.1% (1 week), +8.1% (1 month), +4.2% (3 months), -3.7% (6 months), +58.0% (1 year), +68.4% (year to date).
About Davita Inc.
DaVita is one of the largest providers of dialysis services in the United States, boasting a market share of about 35%. The firm operates over 3,200 facilities worldwide, mostly in the US, and treats about 300,000 patients annually. Government payers dominate US dialysis reimbursement. DaVita receives about two-thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business.
Services-Misc Health & Allied Services, Nec · Listed 1995 · 78,000 employees
Congress activity
Disclosed STOCK Act trades in DVA · 5 recent
| Member | Side | Amount | Traded | Filed | PTR |
|---|---|---|---|---|---|
 Julie Johnson house · D · TX · traded 2025-09-23 | Buy | $1K–$15K | 2025-09-23 | 2026-08-05 | |
 Alan Armstrong senate · R · OK · traded 2026-03-27 | Buy | $1K–$15K | 2026-03-27 | 2026-07-21 | |
Julie Johnson house · D · TX · traded 2025-09-25 | Sell | $1K–$15K | 2025-09-25 | 2025-10-07 | |
 Jerry Moran, senate · R · KS · traded 2023-12-14 | Sell | $1K–$15K | 2023-12-14 | 2024-01-17 | |
 Thomas H Tuberville senate · traded 2023-12-12 | Sell | $1K–$15K | 2023-12-12 | 2024-01-12 |
Insider activity
SEC Form 4 transactions in DVA · open-market 1 sell
| Insider | Side | Shares | Value | Traded | Filed |
|---|---|---|---|---|---|
BERKSHIRE HATHAWAY INC 10% owner · Common Stock · 2026-10-27 | Sell | 382.56K | $69M | 2026-10-27 | 2026-10-29 |
Pullin Dennis W Director · Common Stock · 2026-08-15 | Grant | 278 | — | 2026-08-15 | 2026-08-18 |
Moore Gregory J. Director · Common Stock · 2026-08-15 | Grant | 278 | — | 2026-08-15 | 2026-08-18 |
Schechter Adam H Director · Common Stock · 2026-08-15 | Grant | 278 | — | 2026-08-15 | 2026-08-18 |
DESOER BARBARA J Director · Common Stock · 2026-08-15 | Grant | 278 | — | 2026-08-15 | 2026-08-18 |
Hollar Jason M. Director · Common Stock · 2026-08-15 | Grant | 278 | — | 2026-08-15 | 2026-08-18 |
Arway Pamela M Director · Common Stock · 2026-08-15 | Grant | 278 | — | 2026-08-15 | 2026-08-18 |
YALE PHYLLIS R Director · Common Stock · 2026-08-15 | Grant | 278 | — | 2026-08-15 | 2026-08-18 |
Schoppert Wendy Lee Director · Common Stock · 2026-08-15 | Grant | 278 | — | 2026-08-15 | 2026-08-18 |
YALE PHYLLIS R Director · Common Stock · 2026-05-26 | Gift | 5.04K | $0 | 2026-05-26 | 2026-05-28 |
SEC filings
EDGAR filings in DVA · 9 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, no credit card.
Start free — 7-day trial, no card →Free daily signals by email. Top 3 setups per lane after every close. No account needed.
Unsubscribe anytime · Privacy
Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.